 DANVERS, Mass.--BUSINESS WIRE--Abiomed NASDAQ: ABMD announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79 survival rate at explant. A majority of surviving patients recovered their native heart function without needing further mechanical support or a heart transplant. The study is the first large, multicenter experience examining survival rates with Impella 5.5 with SmartAssist support. It was presented at The Society of 